当前位置: X-MOL 学术J. Am. Coll. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults
Journal of the American College of Cardiology ( IF 21.7 ) Pub Date : 2020-07-01 , DOI: 10.1016/j.jacc.2020.05.016
Zhen Zhou 1 , Richard Ofori-Asenso 2 , Andrea J Curtis 3 , Monique Breslin 1 , Rory Wolfe 3 , John J McNeil 3 , Anne M Murray 4 , Michael E Ernst 5 , Christopher M Reid 6 , Jessica E Lockery 3 , Robyn L Woods 3 , Andrew M Tonkin 3 , Mark R Nelson 1
Affiliation  

BACKGROUND There is clinical uncertainty regarding the benefits and harms of prescribing statins in healthy subjects ≥70 years of age. OBJECTIVES The aim of this study was to examine the association among statins, dementia-free and disability-free survival, and cardiovascular disease (CVD) among healthy older adults using data from the ASPREE (Aspirin in Reducing Events in the Elderly) trial. METHODS ASPREE was a randomized trial of 19,114 community-dwelling persons in Australia and the United States ≥65 years of age and free of documented CVD, dementia, and disability. Data were collected for those ≥70 years of age, and participants who took statins at baseline were compared with those who did not using Cox proportional hazards regression with inverse probability weighting. The primary outcome, referred to as "disability-free survival," was a composite of all-cause mortality, dementia, or persistent physical disability. Other outcomes included the individual components of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction, and stroke. RESULTS Of the 18,096 included participants (median age 74.2 years, 56.0% women), 5,629 took statins at baseline. Over a median follow-up period of 4.7 years, baseline statin use was not associated with disability-free survival or with the risk for all-cause mortality or dementia. However, it was associated with lower risks for physical disability and all cardiovascular outcomes. CONCLUSIONS Among healthy community-dwelling adults ≥70 years of age, statin use may be beneficial for preventing physical disability and CVD but not beneficial for prolonging disability-free survival or avoiding death or dementia. Future clinical trials are needed to confirm these findings.

中文翻译:


他汀类药物的使用与健康老年人无残疾生存和心血管疾病的关系



背景 对于 70 岁以上的健康受试者服用他汀类药物的益处和危害存在临床不确定性。目的 本研究的目的是利用 ASPREE(阿司匹林减少老年人事件)试验的数据,探讨健康老年人中他汀类药物、无痴呆和无残疾生存率以及心血管疾病 (CVD) 之间的关联。方法 ASPREE 是一项随机试验,对象为澳大利亚和美国 19,114 名社区居民,年龄≥65 岁,无 CVD、痴呆和残疾记录。收集年龄≥70岁的参与者的数据,并将基线时服用他汀类药物的参与者与未使用带有逆概率加权的Cox比例风险回归的参与者进行比较。主要结局被称为“无残疾生存率”,是全因死亡率、痴呆或持续性身体残疾的综合结果。其他结局包括复合结局的各个组成部分、主要不良心血管事件、致命性CVD、心肌梗死和中风。结果 在 18,096 名参与者中(中位年龄 74.2 岁,56.0% 为女性),5,629 人在基线时服用他汀类药物。在 4.7 年的中位随访期内,基线他汀类药物的使用与无残疾生存或全因死亡或痴呆的风险无关。然而,它与较低的身体残疾和所有心血管结局风险相关。结论 在≥70岁的健康社区居住成年人中,使用他汀类药物可能有利于预防身体残疾和心血管疾病,但无益于延长无残疾生存期或避免死亡或痴呆。需要未来的临床试验来证实这些发现。
更新日期:2020-07-01
down
wechat
bug